• Orlyk O. S. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine; 2 DNU, Center of Innovative Medical Technologies, National Academy of Sciences of Ukraine, Kiev, Ukraine




diabetes mellitus, vildagliptin, hypoglycemia, glycated hemoglobin


The article highlights modern approaches to treatment, criteria for compensating for diabetes mellitus,
taking into account the latest international recommendations. A review of clinical studies in which the sugarlowering ability of vildagliptin was studied, both in monotherapy and in a double, triple combination with
other oral sugar-lowering drugs and also in combination with insulin, is presented. The results of studying
the effect of vildagliptin on endothelial function in patients with type 2 diabetes and hypertension, the ability
to influence biomarkers associated with the progression of thrombosis, inflammation and hypercoagulation in
diabetes are presented. The results of a study are presented, in which the effectiveness of representatives of
the class of drugs and DPP-4 was compared with each other, as a result of vildagliptin, a marked reduction in
fasting glycemia was compared with sitagliptin. Also, the article presents clinical cases in which the feasibility
and effectiveness of prescribing vildagliptin to various categories of patients with type 2 diabetes are clearly
visible. The clinical situation of an elderly patient with type 2 diabetes, who was on intensive insulin therapy,
had frequent hypoglycemia, and significant cognitive impairment; the appointment of vildagliptin allowed to
avoid hypoglycemia, improve the patient's quality of life and significantly simplify the scheme of hypoglycemic
therapy. The article also presents the clinical case of a patient with newly diagnosed diabetes and obesity in
whom Metformin intolerance is diagnosed; in this situation, vildagliptin was prescribed as a first-line drug
against the background of a modification of lifestyle and diet; Such therapeutic tactics once again reminds of an
individual approach to the patient and the possibility of choosing vildagliptin as the start of the treatment of
type 2 diabetes.


Prudius PG, Vlasenko MV, Kostjuk NV. Dostupno pro cukrovyj diabet, Vinnycja, 2018: 3-4.

United States Renal Data System. USRDS 2007.

Pyram R, et al. Maturitas. 2012; 71: 94-103; doi: http://doi.org/10.1016/ j.maturitas.2011.11.009.

Middleton RJ, et al. Nephrol Dial Transplant. 2006; 21:88-92. doi: http://doi.org/10.1093/ndt/gfi163.

Kendall DM, et al. Am J Med 2009; 122(6): S37-S50 doi: http://doi.org/10.1016/j.amjmed.2009.03.015.

Vlasenko MV, Man’kovs’kyj BM. Taktyka vedennja hvoryh na cukrovyj diabet. Posibnyk v tablycjah (dlja endokrynologiv), Kyi’v, 2018:19p.

Chen XW, He ZX, Zhou ZW, et al. Clin Exp Pharmacol Physiol. 2015; 15. doi: http://doi.org/10.1111/1440-1681.12455.

Ametov AS. Saharnyj diabet 2 tipa: problemy i reshenija, Moskva, 2011: 704 p.

Yavropoulou MP, Pikilidou M, Kotsa K, et al. J Diabetes Metab Disord. 2015; 22:14-68. doi: http://doi.org/10.1186/ s40200-015-0194-6.

Garber AJ, et al. Endocrine Pract. 2018; 24(1). doi: http://doi.org/10.4158/CS-2017-0153.

Bosi E, et al. Diabetes Care. 2007; 30: 890-895. doi: http://doi.org/10.2337/dc06-1732.

Hirose T, Suzuki M, Tsumiyama I. Diabetes Ther. 2015; 6(4): 559-571. doi: http://doi.org/


Barnett AH, Charbonnel B, Moses RG, Kalra S. Curr Med Res Opin. 2015; 31(10): 1919-1931. doi: http://doi.org/10.1185/03007995. 2015.1081589.

Khan S, Khan S, Panda BP, et al. Exp Opin Ther Targets. 2015;19(12): 1607-1616. doi: http://doi.org/10.1517/14728222. 2016.1086338.

Cosenso-Martin LN, Giollo-Junior LT, Martineli DD, et al. Diabetol Metab Syndr. 2015; 26(7): 70. doi: http://doi.org/ 10.1186/s13098-015-0062-z.

Marfella R, Barbieri M, Grella R, et al. J Diab Compl 2010; 24(2): 79-83. doi: http://doi.org/10.1016/j.jdiacomp.2009.01.004.

Neumiller JJ. J Am Pharm Assoc. 2009; 49(1): 16-29. doi: http://doi.org/10.1331/JAPhA.2009.09078.

Sakamoto M, Nishimura R, Irako T, et al. Cardiovasc Diabetol. 2012: 11-92. doi: http://doi.org/ 10.1186/1475-2840-11-92




How to Cite

Orlyk, O. S. (2019). EXPERIENCE OF VILDAGLIPTIN USE IN VARIOUS CLINICAL SITUATIONS. Problems of Endocrine Pathology, 70(4), 81-89. https://doi.org/10.21856/j-PEP.2019.4.11